The cardio-protective effects of dual SGLT1/2 inhibition in patients with type 2 diabetes and worsening heart failure was recently reported (Bhatt et al., 2021), but it is unknown whether these benefits will extend to non-diabetic patients and/or those with preserved ejection fraction. Here, SLC5A1 is linked to type 2 diabetes mellitus.